Cocrystal Pharma (COCP)
(Real Time Quote from BATS)
$1.95 USD
-0.15 (-7.14%)
Updated May 16, 2024 01:56 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
COCP 1.95 -0.15(-7.14%)
Will COCP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for COCP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for COCP
Noble Financial Sticks to Their Buy Rating for Cocrystal Pharma (COCP)
Cocrystal Pharma: A Strong Buy on Innovative Antiviral Pipeline and Market Potential
COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024
Cocrystal Pharma GAAP EPS of -$0.39 beats by $0.15
Cocrystal Pharma reports Q1 EPS (39c) vs (64c) last year